Financials
Financial year 2025
The BioPharmaTechnology House from Meerhout, company number BE0866427061, closed financial year 2025 with a result of € 20,100 after tax. For that financial year The BioPharmaTechnology House recorded a gross margin of € 120,502 and equity of € 470,910. Compared with financial year 2024, the result moved from € -3,846 to € 20,100. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 30, 2025.
€ 470,910
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 20,100
▲ still € 3,846 loss in 2024
Profit after tax over the fiscal year.
€ 144,723
▲ 161% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1,718 paid out
9 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 5,012
▼ 58% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 29,786
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 26,176
▼ 34% vs 2024
€ 9,051 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 12,238
▼ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 26,109
▲ 1% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 81,637 | € 82,312 | € 133,005 | € 120,502 | ▼ 9% |
| Profit after taxes | € -25,105 | € -5,582 | € -3,846 | € 20,100 | ▲ € 23,946 |
| Equity | € 463,623 | € 458,041 | € 452,528 | € 470,910 | ▲ 4% |
| Total debts | € 197,767 | € 219,915 | € 221,302 | € 223,451 | ▲ 1% |
| Cash | € 134,558 | € 179,025 | € 55,398 | € 144,723 | ▲ 161% |
| Land & buildings | € 451,489 | € 415,099 | € 378,282 | € 342,222 | ▼ 10% |
| Retained profit | € 445,023 | € 439,441 | € 433,928 | € 452,310 | ▲ 4% |
| Dividend | € 0 | € 0 | € 1,666 | € 1,718 | ▲ 3% |
| Bank debt | € 24,229 | € 58,318 | € 39,952 | € 26,176 | ▼ 34% |
| Balance sheet total | € 661,390 | € 677,956 | € 673,830 | € 694,361 | ▲ 3% |
Key figures of The BioPharmaTechnology House, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to The BioPharmaTechnology House?
What happened at The BioPharmaTechnology House in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 20,100. Source: NBB ↗
- New establishment in Meerhout. KBO
- Start of the company according to the CBE. KBO
In short
From € 25,105 loss in 2022 to € 20,100 profit in 2025.
Paid € 21,210 in corporate taxes since 2022.
Best year ever: 2025, with € 20,100 profit.
Paid out € 3,384 in dividends to the owners in total.
A new publication or filing at The BioPharmaTechnology House? We notify you, reason included.
Follow The BioPharmaTechnology HouseDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind The BioPharmaTechnology House are Veerle VAN DEN BRANDE and Mario PEETERS.
Directors
According to the 2025 annual accounts
Veerle VAN DEN BRANDE
Director
Mario PEETERS
Director
Establishments
Establishment units
Physical locations of this company
De Biezen 22
2450 Meerhout
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Outlook.com (free)
Hosting
COMBELL-AS, BE
Domain
Domain
bpth.com
Registered
2004-06-11
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2026-06-11
Website info
Features
Security
Details
- Company number
- 0866.427.061
- VAT number
- BE 0866.427.061
- Registered office
- De Biezen 22, 2450 Meerhout
- Names & denominations
- The BioPharmaTechnology House
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 July 2004
- Peppol
- Active · Active since 1 Oct 2025
- Contact
- bpth.com [email protected]
- Activities · NACE
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computeradviesbureaus
Computerconsultancy-activiteiten
Computerinfrastructuur, gegevensverwerking, hosting en aanverwante activiteiten
Handelsbemiddeling in de groothandel in machines, apparaten en werktuigen voor de industrie en in schepen en luchtvaartuigen
Activiteiten van interieurarchitecten
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts
Technische studiën en ingenieursactiviteiten
+3